TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10399947

Group type: EXPERIMENTAL
Intervention: Germline brca2 alterations
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Personal history of breast cancer
Number of subjects: 62

Group type: COMPARATOR
Intervention: Family history of breast/ovarian cancer or OM
Number of subjects: 62
Study: 7754763

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1970032

Group type: EXPERIMENTAL
Intervention: Oestrogen-progesterone (0.05 mg ethinyloestradiol plus 1 mg norethisterone daily for 6 months)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (6 months)
Number of subjects: 10
Study: 531563

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg twice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 18
Study: 31868037

Group type: EXPERIMENTAL
Intervention: Augmented communication-input (AC-I)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Augmented communication-output (AC-O)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Spoken communication (SC)
Number of subjects: 62
Study: 29950824

Group type: EXPERIMENTAL
Intervention: Thoracopelvic assisted movement device training (12 sessions)
Number of subjects: 19
Study: 26525165

Group type: EXPERIMENTAL
Intervention: Psychologist-led, individualised cognitive behavioural intervention (PI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurse-led, minimal contact self-management condition (Control)
Number of subjects: 0
Study: 22952290

Group type: COMPARATOR
Intervention: Resistance exercise (RE) at 40% intensity
Number of subjects: 18

Group type: COMPARATOR
Intervention: Resistance exercise (RE) at 80% intensity
Number of subjects: 18
Study: 21610207

Group type: EXPERIMENTAL
Intervention: GSK1521498 (oral solution and capsule formulations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK1521498 (10-150 mg single doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK1521498
Number of subjects: 0
Study: 21046866

Group type: EXPERIMENTAL
Intervention: Blacking out the eyes
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Covering the eyes and nose
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Covering the T-shaped area (eyes, nose, and mouth)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study: 17937689

Group type: EXPERIMENTAL
Intervention: CUPDAY Milk (probiotic-prebiotic milk product)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 496
Study: 15192648

Group type: EXPERIMENTAL
Intervention: Trientine hydrochloride (250 mg daily before a meal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trientine hydrochloride (750 mg daily, divided into 3 doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trientine hydrochloride (both groups)
Number of subjects: 24
Study: 11756065

Group type: EXPERIMENTAL
Intervention: Zinc (20 mg/d for 14 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin A (60000 retinol equivalents on day 14)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Zinc plus Vitamin A
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9678728

Group type: EXPERIMENTAL
Intervention: Benign effusions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Malignant effusions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tumor classification T3 or higher
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clear cell and papillary tumors
Number of subjects: 15
Study: 7988944

Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 2846791

Group type: EXPERIMENTAL
Intervention: Vincristine (VCR) plus Dactinomycin (AMD)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Vincristine (VCR) plus Dactinomycin (AMD) plus Doxorubicin (ADR)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Right side or whole abdomen irradiation
Number of subjects: 303

Group type: COMPARATOR
Intervention: Left side irradiation
Number of subjects: 303
Study: 31704458

Group type: EXPERIMENTAL
Intervention: Patient-reported stone passage
Number of subjects: 382

Group type: COMPARATOR
Intervention: No patient-reported stone passage
Number of subjects: 382
Study: 29446830

Group type: EXPERIMENTAL
Intervention: Ketone monoester (Kme) supplement (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.45 ml kg-1 body weight)
Number of subjects: 20
Study: 27281341

Group type: EXPERIMENTAL
Intervention: Gaze cues provided by the robotic avatar
Number of subjects: 43

Group type: COMPARATOR
Intervention: No gaze cues provided by the robotic avatar
Number of subjects: 43
Study: 25179033

Group type: EXPERIMENTAL
Intervention: Communication facilitator intervention
Number of subjects: 14
Study: 23176593

Group type: EXPERIMENTAL
Intervention: Group MC - Music concert delivering obesity-preventing/cardiovascular health messages
Number of subjects: 2107

Group type: COMPARATOR
Intervention: Group HB - Participatory class providing the same information involving the description and making of a healthy breakfast
Number of subjects: 2107

Group type: EXPERIMENTAL
Intervention: Group MC - Music concert
Number of subjects: 2107

Group type: COMPARATOR
Intervention: Group HB - Participatory class
Number of subjects: 2107

Group type: EXPERIMENTAL
Intervention: Children deemed overweight/obese prior to the interventions
Number of subjects: 2107
Study: 20723645

Group type: EXPERIMENTAL
Intervention: 7-day Holter monitoring
Number of subjects: 63

Group type: COMPARATOR
Intervention: 1-day Holter monitoring
Number of subjects: 63
Study: 18931059

Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping (EAM) alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Computed tomographic (CT) integration with EAM (Cartomerge)
Number of subjects: 80
Study: 15967861

Group type: EXPERIMENTAL
Intervention: Fenoldopam at 0.05 microg/kg per minute for 24 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dopamine at 2.5 microg/kg per minute for 24 hours
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fenoldopam and Dopamine (both groups)
Number of subjects: 80
Study: 11817593

Group type: EXPERIMENTAL
Intervention: Urinary glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Urinary C-terminal crosslinking telopeptide of type II collagen (CTX-II)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Serum matrix metalloproteinase 3 (MMP-3)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Baseline serum level of C-reactive protein (CRP)
Number of subjects: 116
Study: 9042744

Group type: EXPERIMENTAL
Intervention: Advance information in the form of stems of multiple-choice comprehension questions
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Advance information on the questions
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control condition (no advance information)
Number of subjects: 2
Study: 2126745

Group type: EXPERIMENTAL
Intervention: Morphine administration in the TPN group
Number of subjects: 8

Group type: COMPARATOR
Intervention: Morphine administration in the non-TPN group
Number of subjects: 8
Study: 6794167

Group type: EXPERIMENTAL
Intervention: 4,000 rads of cobalt radiation for eight days prior to operation
Number of subjects: 124

Group type: COMPARATOR
Intervention: No radiation therapy (control group)
Number of subjects: 124
Study: 31314671

Group type: EXPERIMENTAL
Intervention: Squat Jump from 90° (SJ90)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Self-preferred Knee Angle Jump (SJpref)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Force Platform (FP) Method
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Samozino's (SAM) Method
Number of subjects: 12

Group type: COMPARATOR
Intervention: Three-point Method
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two-point Method
Number of subjects: 12
Study: 30354918

Group type: EXPERIMENTAL
Intervention: Bilateral rTMS plus NMES
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Unilateral rTMS plus NMES
Number of subjects: 64

Group type: COMPARATOR
Intervention: Contralesional 1-Hz rTMS plus NMES
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ipsilesional 10-Hz rTMS plus NMES
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham rTMS plus NMES
Number of subjects: 64
Study: 28124569

Group type: EXPERIMENTAL
Intervention: Double percutaneous aspiration injection (DPAI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 43
Study: 25045857

Group type: EXPERIMENTAL
Intervention: Robot-assisted hysterectomy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Traditional laparoscopic hysterectomy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Traditional minimally invasive hysterectomy (including vaginal hysterectomy)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Robotic-assisted hysterectomy (with preexisting investment)
Number of subjects: 122
Study: 24139986

Group type: EXPERIMENTAL
Intervention: Active PEMF
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo PEMF
Number of subjects: 56
Study: 22520670

Group type: EXPERIMENTAL
Intervention: Algorithm for quantifying absolute risk of colorectal cancer
Number of subjects: 4798
Study: 19178877

Group type: EXPERIMENTAL
Intervention: Supplemented Experimental Subjects (SES)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unsupplemented Experimental Subjects (UES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supplemented Control Subjects (SCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unsupplemented Control Subjects (UCS)
Number of subjects: 40
Study: 17316429

Group type: EXPERIMENTAL
Intervention: 1200 IU/day of alpha-tocopherol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 19
Study: 15179967

Group type: EXPERIMENTAL
Intervention: Acamprosate, 1332-1998 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: No anti-relapse medication (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acamprosate treatment
Number of subjects: 30
Study: 11583207

Group type: EXPERIMENTAL
Intervention: Bronchoscopy with improper connection to the STERIS SYSTEM 1 processor
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bronchoscopy with appropriate connections implemented after the outbreak
Number of subjects: 18
Study: 10615579

Group type: EXPERIMENTAL
Intervention: Participatory organizational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other intervention group
Number of subjects: 0
Study: 8527687

Group type: EXPERIMENTAL
Intervention: Experimental controlled release tablet containing pseudoephedrine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Marketed controlled release pseudoephedrine capsule
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Experimental controlled release tablet containing pseudoephedrine with guaifenesin
Number of subjects: 6
Study: 2196671

Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 697082

Group type: EXPERIMENTAL
Intervention: Bupivacaine epidural anesthesia (168 +/- 7 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tetracaine spinal anesthesia (control group, n=10)
Number of subjects: 10
Study: 31252307

Group type: EXPERIMENTAL
Intervention: Anodal tDCS condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS condition
Number of subjects: 0
Study: 28122270

Group type: EXPERIMENTAL
Intervention: MI-LEAF (training emphasizing an influence of client language)
Number of subjects: 190

Group type: COMPARATOR
Intervention: MI-AU (standard training in MI)
Number of subjects: 190
Study: 26367281

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23649520

Group type: EXPERIMENTAL
Intervention: Exendin(9-39) (Ex-9)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exendin(9-39) (Ex-9) after RYGB
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (Control) after RYGB
Number of subjects: 9
Study: 21450607

Group type: EXPERIMENTAL
Intervention: 12-week walking programme (40 minutes, 5 days per week)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 12-week walking programme
Number of subjects: 28

Group type: COMPARATOR
Intervention: non-exercise group
Number of subjects: 28
Study: 19644384

Group type: EXPERIMENTAL
Intervention: Emtricitabine + Tenofovir DF + Efavirenz (FTC + TDF + EFV)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Lamivudine + Zidovudine + Efavirenz (3TC + ZDV + EFV)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Baseline NNRTI resistance (NNRTI-R)
Number of subjects: 487
Study: 17285269

Group type: EXPERIMENTAL
Intervention: Propolis (500 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15121650

Group type: EXPERIMENTAL
Intervention: Enhanced counseling and support treatment
Number of subjects: 406

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 406
Study: 11704076

Group type: EXPERIMENTAL
Intervention: Extraocular light therapy (15 patients, 4 M, 11 F)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (14 patients, 4 M, 10 F)
Number of subjects: 29
Study: 9382120

Group type: EXPERIMENTAL
Intervention: Pneumococcal and influenza vaccines (PI group)
Number of subjects: 2837

Group type: COMPARATOR
Intervention: Influenza vaccine alone (I group)
Number of subjects: 2837
Study: 2554722

Group type: EXPERIMENTAL
Intervention: HF (high fiber diet with 55 g fiber/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HFS (high fiber diet with 55 g fiber/day and 15 g sucrose three times daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (usual diet with about 30 g fiber/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both high fiber diets (HF and HFS)
Number of subjects: 10
Study: 240014

Group type: EXPERIMENTAL
Intervention: Early continuous negative pressure (CNP) treatment before PaO2 < 50 mm Hg on 70% oxygen
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Early continuous negative pressure (CNP) treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Delayed continuous negative pressure (CNP) treatment
Number of subjects: 23
Study: 31188170

Group type: EXPERIMENTAL
Intervention: aDTM/PRF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (PRF alone)
Number of subjects: 40
Study: 27975116

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula with Lactobacillus rhamnosus GG (EHF-LGG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula with Lactobacillus rhamnosus GG (PHF-LGG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control: Extensively hydrolyzed casein formula (EHF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control: Partially hydrolyzed formula without LGG
Number of subjects: 0
Study: 26649541

Group type: EXPERIMENTAL
Intervention: Educational intervention using reusable learning objects (RLOs) delivered online and through DVD.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 0
Study: 23381898

Group type: EXPERIMENTAL
Intervention: Paclitaxel with S-1 (PS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: S-1 monotherapy
Number of subjects: 82
Study: 21466091

Group type: EXPERIMENTAL
Intervention: NuStep exercise at various workloads (1, 3, 5, and 7) and cadences (60, 80, and 100 steps/min.)
Number of subjects: 40
Study: 19563976

Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary endpoint
Number of subjects: 0
Study: 16198519

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg (CEE/MPA, n=38)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA, n=44)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg (low E2/NETA, n=50)
Number of subjects: 132
Study: 15275797

Group type: EXPERIMENTAL
Intervention: Imagery intervention (professionally developed videotape and 30-min audio tape)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard care (attention-control group)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combined opioid and non-opioid use
Number of subjects: 73
Study: 11736903

Group type: EXPERIMENTAL
Intervention: New sunscreens with zinc oxide and pigmentary grade titanium dioxide as active ingredients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sun E45 (SPF 25)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RoC Total (SPF 25)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New sunscreens
Number of subjects: 0
Study: 9519493

Group type: EXPERIMENTAL
Intervention: Alcohol-specific social relationship indicators
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: General indicators of social relationships
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Functional indicators of social interaction
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: General and alcohol-specific support from friends
Number of subjects: 140
Study: 8214698

Group type: EXPERIMENTAL
Intervention: Propofol infusion supplemented with an epidural block with bupivacaine (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alfentanil infusion intravenously (Group A)
Number of subjects: 20
Study: 3591720

Group type: EXPERIMENTAL
Intervention: Ventilated hood
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 18
Study: 31928249

Group type: EXPERIMENTAL
Intervention: He‐Ne laser irradiation pretreatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no laser irradiation pretreatment)
Number of subjects: 60
Study: 29272253

Group type: EXPERIMENTAL
Intervention: PETN
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 28586293

Group type: EXPERIMENTAL
Intervention: Parental support intervention (counseling for 6 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 44
Study: 25556049

Group type: EXPERIMENTAL
Intervention: Environmental cleaning by infection control professionals
Number of subjects: 23

Group type: COMPARATOR
Intervention: Environmental cleaning by environmental service workers (ESWs)
Number of subjects: 23
Study: 24008128

Group type: EXPERIMENTAL
Intervention: Baseline adenomas from participants who developed metachronous adenomas
Number of subjects: 76

Group type: COMPARATOR
Intervention: Baseline adenomas from participants who remained adenoma free
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Each 10% increase in ALIs
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Best-fit algorithm-based cutoff point of 22.4%
Number of subjects: 76
Study: 21819369

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 19394113

Group type: EXPERIMENTAL
Intervention: Simulation-based curriculum
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group discussion
Number of subjects: 90
Study: 16427357

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 0
Study: 12633213

Group type: EXPERIMENTAL
Intervention: Fiberglass splint material (3M Scotchcast)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aquaplast
Number of subjects: 16
Study: 10710838

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) intervention, n = 47
Number of subjects: 73

Group type: COMPARATOR
Intervention: Wait-list control (WLC), n = 26
Number of subjects: 73
Study: 9378150

Group type: EXPERIMENTAL
Intervention: Cisplatin and cyclophosphamide plus doxorubicin (40 mg/m2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cisplatin and cyclophosphamide plus doxorubicin (50 mg/m2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cisplatin and cyclophosphamide (control)
Number of subjects: 23
Study: 8225214

Group type: EXPERIMENTAL
Intervention: Desmopressin plus terlipressin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Terlipressin alone
Number of subjects: 51
Study: 3877279

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 3 mg/kg/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 6 mg/kg/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 9 mg/kg/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All infusion rates (3, 6, 9 mg/kg/h)
Number of subjects: 60
Study: 29654415

Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo plus letrozole (2.5 mg/day)
Number of subjects: 668
Study: 26843523

Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DPDT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Artificial white light photodynamic therapy (AWLPDT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 22
Study: 24709267

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation during the intensive phase of TB treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: No nutritional supplementation (control group)
Number of subjects: 100
Study: 22672732

Group type: EXPERIMENTAL
Intervention: Respiratory training
Number of subjects: 40
Study: 21034706

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser plus methylaminolevulinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulsed dye laser alone
Number of subjects: 0
Study: 18590344

Group type: EXPERIMENTAL
Intervention: Lansoprazole 0.5 or 1.0 mg/kg/day (neonates), or 1.0 or 2.0 mg/kg/day (infants) for 5 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 48
Study: 16083023

Group type: EXPERIMENTAL
Intervention: Variations in blood flow and dialysate flow
Number of subjects: 48